ascendis pharma glp-1 receptor agonist medications Holding Agonists Prior to Elective Procedures Novo Nordisk signs deal for

High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor

Pfizer recently had to abandon its GLP-1 pill based on safety concerns, she writes

Switching was defined as a change to a different GLP-1 between consecutive months (e.g., January to February 2025)

I welcome hearing from you

7 Notably, the PIONEER-6 (A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes) 1 and AWARD-11 (Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes) 19 studies did not show a worsening of DR or other retinal complications